secwatch.observer — SEC 8-K summary
======================================

Issuer:     CASTLE BIOSCIENCES INC (CSTL)
CIK:        0001447362
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0001447362-24-000059
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Castle Biosciences Q1 revenue $73M (+74% YoY); raises FY2024 guidance to $255-265M
--------------------------------------------------------------------------------

- Q1 revenue $73.0M (+74% YoY); adjusted revenue $71.3M (+64% YoY).
- Net loss narrowed to $2.5M from $29.2M; adjusted EBITDA improved to $10.5M from -$15.1M.
- Total test reports +40% to 20,888; TissueCypher +148%, IDgenetix +90%.
- FY2024 revenue guidance raised to $255-265M from prior $235-240M.
- Cash & marketable securities $239.2M; gross margin 78% (adj. 81%).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447362/000144736224000059/0001447362-24-000059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447362/000144736224000059/cstl-20240502.htm
  HTML page:      https://secwatch.observer/filing/0001447362-24-000059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer